Cabometyx
Drug
Exelixis Inc.
Total Payments
$25.0M
Transactions
36,585
Doctors
7,195
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $23,951 | 10 | 2 |
| 2023 | $12,592 | 1 | 1 |
| 2022 | $14.2M | 9,132 | 2,764 |
| 2021 | $32,660 | 209 | 144 |
| 2020 | $2.2M | 2,336 | 1,206 |
| 2019 | $3.6M | 8,172 | 2,962 |
| 2018 | $2.6M | 8,290 | 3,046 |
| 2017 | $2.2M | 8,435 | 3,035 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.8M | 2,532 | 51.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6.1M | 1,903 | 24.4% |
| Consulting Fee | $3.2M | 260 | 12.7% |
| Travel and Lodging | $1.3M | 3,504 | 5.0% |
| Food and Beverage | $699,162 | 25,673 | 2.8% |
| Grant | $343,000 | 17 | 1.4% |
| Honoraria | $258,720 | 70 | 1.0% |
| Space rental or facility fees (teaching hospital only) | $239,372 | 130 | 1.0% |
| Charitable Contribution | $47,500 | 6 | 0.2% |
| Education | $45,177 | 2,487 | 0.2% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $6,338 | 1 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $6,090 | 1 | 0.0% |
| Royalty or License | $4,000 | 1 | 0.0% |
Payments by Type
Research
$12.8M
2,532 transactions
General
$12.2M
34,053 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Exelixis Inc. | $2.7M | 5 |
| A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris | Exelixis Inc. | $2.2M | 0 |
| A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer | Exelixis Inc. | $1.2M | 3 |
| A Randomized Phase II Trial of Cabozantinib Combined with PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma | Exelixis Inc. | $613,940 | 0 |
| A Phase 2 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma | Exelixis Inc. | $542,384 | 0 |
| A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | Exelixis Inc. | $528,950 | 0 |
| Efficacy of Cabozantinib in combination with immunotherapy in novel mouse models of primary colorectal cancer and liver metastasis | Exelixis Inc. | $397,945 | 0 |
| Cyto-KIK TRIAL CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy (Nivolumab) and Targeted Kinase Inhibition (Cabozantinib) | Exelixis Inc. | $351,542 | 0 |
| ODYSSEY Outcomes in Deferred and immediate sYstemic treatment A prospective observational study to aSSEss the rapidly changing TherapY landscape for Renal Cell Carcinoma (ODYSSEY RCC) | Exelixis Inc. | $285,714 | 0 |
| A Phase II study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | Exelixis Inc. | $282,369 | 0 |
| A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine Refractory Differentiated Thyroid Cancer who have Progressed after Prior VEGFR-Targeted Therapy | Exelixis Inc. | $257,188 | 0 |
| Neoadjuvant Cabozantinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma | Exelixis Inc. | $253,721 | 0 |
| Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery | Exelixis Inc. | $206,379 | 0 |
| GU-187 Phase II Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma | Exelixis Inc. | $181,584 | 0 |
| Phase II Clinical Trial Evaluating Cabozantinib and Pembrolizumab in Metastatic Pancreatic Cancer | Exelixis Inc. | $177,720 | 0 |
| Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CABINET) | Exelixis Inc. | $175,139 | 0 |
| A Phase 1 Study of the Combination of Cabozantinib with TrifluridineTipiracil (TAS-102) in patients with metastatic colorectal adenocarcinoma (mCRC) | Exelixis Inc. | $167,415 | 0 |
| Phase 2 Study of Cabozantinib Combined with Pembrolizumab in Metastatic or Recurrent Gastric and Gastroesophageal Adenocarcinoma mGC) | Exelixis Inc. | $166,227 | 0 |
| Phase 12 Trial to Evaluate Cabozantinib in Patients with Advanced Hepatocellular Carcinoma with Child Pugh Class B Cirrhosis after First-Line Therapy | Exelixis Inc. | $163,517 | 0 |
| The Genetics of Endocrine Neoplasia A Registry for Patients with Medullary Thyroid Carcinoma | Exelixis Inc. | $150,000 | 0 |
Top Doctors Receiving Payments for Cabometyx
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Baltimore, MD | $14.2M | 2,673 |
| , M.D | Internal Medicine | New York, NY | $1.5M | 214 |
| , M.D | Dermatology | San Francisco, CA | $734,686 | 21 |
| , M.D | Pulmonary Disease | Park Ridge, NJ | $299,225 | 46 |
| , M.D | Medical Oncology | San Antonio, TX | $248,529 | 271 |
| , M.D | Medical Oncology | Stony Brook, NY | $206,026 | 159 |
| , MD | Medical Oncology | Mcallen, TX | $199,297 | 206 |
| , M.D | Internal Medicine | Thousand Oaks, CA | $194,141 | 46 |
| , MD | Hematology & Oncology | Towson, MD | $189,124 | 161 |
| , MD | Medical Oncology | Detroit, MI | $174,336 | 145 |
| , DO,PHARMD | Medical Oncology | Dallas, TX | $171,784 | 112 |
| , MD | Hematology & Oncology | Berwyn, IL | $156,061 | 124 |
| , M.D | Internal Medicine | Madison, CT | $129,809 | 21 |
| Anthony Meluch | — | Nashville, TN | $123,443 | 119 |
| , M.D | Medical Oncology | Chapel Hill, NC | $121,608 | 113 |
| , M.D | Medical Oncology | San Francisco, CA | $120,006 | 5 |
| , MD | Internal Medicine | Charlotte, NC | $114,664 | 116 |
| , M.D | Hematology & Oncology | Durham, NC | $114,608 | 107 |
| , M.D | Medical Oncology | Durham, NC | $112,553 | 141 |
| Randy Sweis | Hematology & Oncology | Chicago, IL | $103,665 | 100 |
| , MD | Medical Oncology | La Jolla, CA | $99,797 | 124 |
| , M.D., PH.D | Medical Oncology | Orange, CA | $95,533 | 97 |
| , MD | Gastroenterology | Cleveland Heights, OH | $91,728 | 99 |
| , M.D | Medical Oncology | Chevy Chase, MD | $90,342 | 86 |
| , M.D | Hematology & Oncology | Miami, FL | $87,419 | 84 |
Ad
Manufacturing Companies
- Exelixis Inc. $24.9M
- Ipsen Innovation $71,363
- Ipsen Pharma SAS $26,550
- Ipsen Biopharmaceuticals, Inc $923.36
Product Information
- Type Drug
- Total Payments $25.0M
- Total Doctors 7,195
- Transactions 36,585
About Cabometyx
Cabometyx is a drug associated with $25.0M in payments to 7,195 healthcare providers, recorded across 36,585 transactions in the CMS Open Payments database. The primary manufacturer is Exelixis Inc..
Payment data is available from 2017 to 2024. In 2024, $23,951 was paid across 10 transactions to 2 doctors.
The most common payment nature for Cabometyx is "Unspecified" ($12.8M, 51.3% of total).
Cabometyx is associated with 20 research studies, including "Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors" ($2.7M).